幽门螺杆菌根除失败后再治疗延迟增加上消化道出血风险
香港全境回顾性队列纳入70518例首次接受克拉霉素三联疗法的幽门螺杆菌感染者,其中8330例(11.8%)需再治疗。与无需再治疗者相比,再治疗者上消化道出血风险更高(aHR 1.50,95%CI 1.34-1.69),且风险随再治疗延迟而递增。
要点
- 根除失败需再治疗者上消化道出血风险显著高于初次成功者。
- 再治疗延迟越长,出血风险越高,>12个月者aHR达1.68。
- 建议考虑在3个月内早期再治疗以降低后续出血风险。
核心结论
- 初始幽门螺杆菌根除失败者较初次治疗成功者上消化道出血风险增加,且再治疗延迟越长风险越高。
研究设计与样本
- 香港全境回顾性队列研究,纳入2003年1月至2012年12月首次接受克拉霉素三联疗法的70518例幽门螺杆菌感染者。
- 其中8330例(11.8%)初始治疗失败需再治疗,按初始至最终根除时间分为≤3个月、3-12个月和>12个月三组。
- 随访自末次幽门螺杆菌治疗处方后30天至非静脉曲张性上消化道出血住院、死亡或研究结束(2016年6月30日),中位随访7.65年。
主要发现
- 需再治疗者总体上消化道出血风险高于无需再治疗者(aHR 1.50,95%CI 1.34-1.69)。
- 再治疗时间≤3个月者上消化道出血aHR为1.16(95%CI 0.88-1.54)。
- 再治疗时间3-12个月者上消化道出血aHR为1.35(95%CI 1.07-1.69)。
临床怎么用
- 对初始幽门螺杆菌根除失败者应尽早安排再治疗,考虑3个月内进行,以降低后续上消化道出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Little is known about risk of upper gastrointestinal bleeding (UGIB) in patients failed by Helicobacter pylori eradication therapy. We investigated the effects of different time until retreatment, after failure of initial H pylori eradication therapy, on subsequent risk of UGIB. METHODS: We performed a territory-wide retrospective cohort study of 70,518 patients with H pylori infection who had received their first course of clarithromycin-based triple therapy from January 2003 through December 2012 in Hong Kong. Patients who required retreatment after failed initial therapy (n = 8330, 11.8%) were categorized based on time between initial and final H pylori eradication (3 months or less, 3-12 months, and more than 12 months). We collected clinical data from 30 days after prescription of the last course of H pylori therapy until hospitalization for non-variceal UGIB, death, or the end of the study (30 Jun 2016; median follow-up time, 7.65 years). The primary outcome was difference in development UGIB (determined from ICD-9 codes) between patients who required retreatment and those who did not (reference group). RESULTS: Compared with the reference group, patients who required retreatment had an overall higher risk of UGIB, even after last eradication therapy (adjusted hazard ratio (HR), 1.50, 95% CI, 1.34-1.69). There was a progressive increase in risk of UGIB with longer time from initial until final eradication therapy: hazard ratio for time less than 3 months, 1.16; 95% CI, 0.88-1.54, hazard ratio for time 3-12 months, 1.35; 95% CI, 1.07-1.69, and hazard ratio for time more than 12 months, 1.68; 95% CI, 1.46-1.94 (P for trend = .038). CONCLUSION: In a retrospective study of patients in Hong Kong, we found that those failed by initial H pylori eradication have an increased risk of UGIB, compared to patients who responded to the initial therapy. Risk increased progressively with longer time until retreatment. Early retreatment within 3 months should be considered to minimize subsequent UGIB risk.
引用
- Guo CG, Cheung KS, Zhang F, et al. Delay in Retreatment of Helicobacter pylori Infection Increases Risk of Upper Gastrointestinal Bleeding. Clin Gastroenterol Hepatol. 2020. PMID: 32289532. doi:10.1016/j.cgh.2020.03.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。